Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-02-17 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Investor Presentation
Regulatory Filings
2020-02-17 English
Press Release
Regulatory Filings
2020-02-17 English
Please find enclosed the Investors Presentation (Q3''FY20) February 2020, based on the financial performance of the Company for the Quarter and Nine months ended December 31, 2019.
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q3'FY20) February 2020' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter and nine months ended 31 December 2019, including revenue, profit, segment-wise growth, and product sales. The content is structured as a presentation with charts and highlights, typical of investor presentations. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a brief announcement or a certification but a detailed presentation aimed at investors. Therefore, the document fits the category of an Investor Presentation (IP). The document length (over 14,000 characters) and detailed financial data support this classification with high confidence.
2020-02-17 English
Morepen Laboratories Ltd has informed BSE regarding issuance of duplicate share Certificates by the Company
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about informing the exchanges about duplicate share certificates issued to shareholders. There is no financial data, no report attached or referenced as being published, no earnings or management discussion, no voting results, no capital changes, or other report types. This is a regulatory announcement related to share certificates, which does not fit into financial reports or other specific categories. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit elsewhere. The document length is short (2780 characters), and it is not an announcement of a report publication but a direct regulatory communication.
2020-02-15 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Morepen Laboratories Limited addressed to stock exchanges, dated 14/02/2020. It reports the outcome of a Board of Directors meeting held on 14 February 2020. The key content includes approval of unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2019, along with a limited review report by statutory auditors. The document also mentions corporate actions such as amendment of the Memorandum of Association and incorporation of a wholly owned subsidiary. The presence of detailed financial data for the quarter and nine months, including revenue, expenses, and profit before tax, indicates this is a comprehensive interim financial report. The document is about quarterly and nine-month financial results, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report publication, nor a short earnings release, but a substantive financial report with actual financial statements and analysis. Therefore, the correct classification is IR with high confidence.
2020-02-14 English
Please find attached Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine-months ended 31st December, 2019, pursuant to Regulation 33 of the ....
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Morepen Laboratories Limited addressed to stock exchanges (NSE and BSE) dated 14/02/2020. It reports the outcome of a Board of Directors meeting held on 14 February 2020. The key content includes approval of unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2019, along with a limited review report by statutory auditors. The document also mentions corporate actions such as amendment of the Memorandum of Association and incorporation of a wholly owned subsidiary. The presence of detailed financial data for the quarter and nine months, including revenue, expenses, and profit before tax, indicates this is a comprehensive interim financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-02-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.